RBD-Fc-based COVID-19 vaccine candidate induces highly potent SARS-CoV-2 neutralizing antibody response
Zezhong Liu(Ministry of Education), Shibo Jiang(Shanghai Medical College of Fudan University), Tianlei Ying(Shanghai Medical College of Fudan University), Zhenghong Yuan(Shanghai Medical College of Fudan University), Lu Lu(Shanghai Medical College of Fudan University), Qian Wang(Shanghai Medical College of Fudan University), Xinling Wang(Fudan University), Youhua Xie(Shanghai Medical College of Fudan University), Chenjian Gu(Washington University in St. Louis), Xia Cai(Fudan University), Jie Zhou(Fudan University), Yanling Wu(Shanghai Medical College of Fudan University), Wei Xu(Beijing Geriatric Hospital), Di Qu(Xijing Hospital), Shuai Xia(Shanghai Medical College of Fudan University)
Cited by 213
Related Papers
Human Infection with a Novel Avian-Origin Influenza A (H7N9) Virus
|New England Journal of Medicine|2013|2.4k
Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion
|Cell Research|2020|1.4k
Fusion mechanism of 2019-nCoV and fusion inhibitors targeting HR1 domain in spike protein
|Cellular and Molecular Immunology|2020|759
Attenuated replication and pathogenicity of SARS-CoV-2 B.1.1.529 Omicron
|RePEc: Research Papers in Economics|0|647
Etiological and epidemiological features of acute respiratory infections in China
|Nature Communications|2021|530